Therapy Areas: Central Nervous System
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
28 January 2026 - French medical imaging company Guerbet (Euronext Paris:GBT) announced on Tuesday that it has received approval from the European Commission for a new indication in children from birt...
Insilico Medicine signs co-development collaboration agreement with Hygtia Therapeutics
21 January 2026 - Insilico Medicine (HKEX: 3696), a Hong Kong-based clinical-stage biotechnology company that utilises generative artificial intelligence (AI), announced on Tuesday that it has signed ...
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
3 December 2025 - Rare disease pharmacy solutions provider Orsini announced on Tuesday that it has been chosen as a specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve), an FDA-appro...
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering u...
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
7 November 2025 - Clinical-stage biotechnology company MavriX Bio and AS2Bio, a drug development accelerator established by the Foundation for Angelman Syndrome Therapeutics (FAST), announced on Thurs...
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
8 October 2025 - Precision NeuroMed (PNM), a clinical-stage biotechnology company developing advanced drug delivery technologies for central nervous system (CNS) diseases, announced on Tuesday that th...